Among Medicare enrollees, there was substantial between-practice variation in the use of second-generation diabetes drugs between 2007 and 2015, according to a study published in JAMA Network Open. Data also revealed a concentration of use among a few prescribers and practices, who were responsible for widespread early diffusion.
Among Medicare enrollees, there was substantial between-practice variation in the use of second-generation diabetes drugs between 2007 and 2015, according to a study published in JAMA Network Open. Data also revealed a concentration of use among a few prescribers and practices, who were responsible for widespread early diffusion.
More than 30 million Americans, roughly 10% of the adult population, had diabetes in 2015, and an additional 1.5 million new cases are diagnosed annually. The majority of new diabetes cases are type 2 diabetes (T2D). Within the past 17 years, among all chronic diseases, “diabetes had the largest increase in annual spending from 1996 to 2013—an increase of $64 billion, $44 billion (69%) of which was spent on prescription drugs,” authors write.
To investigate how second-generation drugs diffused into clinical practices among Medicare enrollees, researchers conducted a population-based, cross-sectional study that included data from all Medicare Part A, B, and D enrollees who first received drug therapy in January 2007. Data were collected through December 2015, and all patients with type 1 diabetes were excluded from the study.
This time period was selected because it preceded when “second-generation diabetes drugs had demonstrated additional cardiovascular benefits and before they were recommended by clinical guidelines.”
Diabetes medications were classified as first-generation if they were approved before 2000, whereas second-generation medications were approved after 2000. The latter generation included dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Researchers considered any practice with use rates of second-generation drugs more than 1 SD over the mean as high-prescribing.
In total, 77,515 individuals were prescribed a second-generation drug as first-line treatment within the study window. The cohort had an average age of 76 years, and the majority were female (57.7%).
Data showed that by December 2015:
Further analyses revealed that “beneficiaries in high-prescribing practices were more than 3-fold more likely to receive DPP-4 inhibitors, 24-fold more likely to receive GLP-1 receptor agonists, and 60-fold more likely to receive SGLT-2 inhibitors compared with beneficiaries in low-prescribing practices.”
Researchers found that practices affiliated with an academic center tended to prescribe first-generation drugs to a higher proportion of patients compared with second-generation drugs. Practices owned by hospitals also prescribed first-generation drugs to a higher proportion of patients than those receiving second-generation medication.
“During this time, metformin, glipizide, and glyburide (first-generation diabetes drugs) were available as $4 generics while second-generation drugs cost between $300 and $500 per month,” authors wrote. They continued, “between 2007 and 2015, 7% of Medicare patients newly treated for T2D were prescribed comparatively expensive second-generation diabetes drugs.”
Investigators hypothesized that specific aspects of the drugs may have affected early diffusion, in addition to potential early signals of benefit in patients with specific comorbidities. However, because the study was conducted among Medicare beneficiaries, authors cautioned that findings may not be generalizable to younger populations.
“This variation in practice patterns highlights a potential shortfall of traditional cost containment mechanisms for prescription drugs and opportunities to improve the value of early diabetes care,” the researchers concluded.
Reference
Gilstrap LG, Blair RA, Huskamp HA, et al. Assessment of second-generation diabetes medication initiation among Medicare enrollees from 2007 to 2015. JAMA Netw Open. Published online May 22, 2020. doi:10.1001/jamanetworkopen.2020.5411
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More